Wide Ranks

ALEC

Alector, Inc.

2.54

Top Statistics
Market Cap 249 M Forward PE -2.08 Revenue Growth 68.40 %
Current Ratio 3.29 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -257.54 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.9770 Enterprise / Revenue -2.82 Price To Sales Trailing12 Months 4.05
Profitability
Profit Margins -257.54 % Operating Margins -301.32 %
Balance Sheet
Total Cash 457 M Total Cash Per Share 4.67 Total Debt 34 M
Total Debt To Equity 29.12 Current Ratio 3.29 Book Value Per Share 1.21
All Measures
Short Ratio 655.00 % Message Board Id finmb_249249899 Shares Short Prior Month 4 M
Return On Equity -1.13 City South San Francisco Uuid 92f69e0b-76d9-379a-b19d-23f78cf134c6
Previous Close 2.57 First Trade Date Epoch Utc 1 B Book Value 1.21
Beta 0.6570 Total Debt 34 M Volume 2 M
Price To Book 2.10 Fifty Two Week Low 2.37 Total Cash Per Share 4.67
Total Revenue 61 M Shares Short Previous Month Date 1 B Target Median Price 9.00
Audit Risk 7 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins -301.32 % Target Mean Price 10.28
Net Income To Common -158408992 Short Percent Of Float 0.0584 Implied Shares Outstanding 97 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 457 M Next Fiscal Year End 1 B
Revenue Per Share 0.6610 Held Percent Insiders 0.1008 Ebitda Margins -288.41 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 2.57 Target Low Price 3.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.75 Open 2.60
Free Cashflow -66916500 State CA Dividend Yield 0.00 %
Return On Assets -0.1925 Time Zone Short Name EST Board Risk 2
Trailing Eps -1.71 Day Low 2.45 Address1 131 Oyster Point Boulevard
Shares Outstanding 97 M Compensation Risk 8 Price Hint 4
Target High Price 29.50 Website https://www.alector.com 52 Week Change -0.5304
Average Volume 790107 Forward Eps -1.48 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 320.80 % Is_sp_500 False
Regular Market Day High 2.63 Profit Margins -257.54 % Debt To Equity 29.12
Fifty Two Week High 8.90 Day High 2.63 Shares Short 4 M
Regular Market Open 2.60 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue -2.82 Revenue Growth 68.40 % Shares Percent Shares Out 0.0411
Operating Cashflow -220947008 Currency USD Time Zone Full Name America/New_York
Market Cap 249 M Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Biotechnology Long Name Alector, Inc.
Overall Risk 6 Regular Market Day Low 2.45 Held Percent Institutions 0.8607
Current Price 2.54 Address2 Suite 600 Enterprise To Ebitda 0.9770
Financial Currency USD Current Ratio 3.29 Gross Margins -204.35 %
Industry Disp Biotechnology Number Of Analyst Opinions 9 Country United States
Float Shares 82 M Two Hundred Day Average 5.31 Governance Epoch Date 1 B
Enterprise Value -173324528 Price To Sales Trailing12 Months 4.05 Forward PE -2.08
Regular Market Volume 2 M Ebitda -177394000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.

Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease.

Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases.

The company was founded in 2013 and is headquartered in South San Francisco, California.